Last Updated : April 19, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
TBC | ruxolitinib | atopic dermatitis | Suspended | |||
TBC | danicopan | Paroxysmal nocturnal hemoglobinuria (PNH) | Received | |||
TBC | pegcetacoplan | Geographic atrophy secondary to age-related macular degeneration | Pending | |||
TBC | cabotegravir | HIV-1 infection, pre-exposure prophylaxis | Active | |||
TBC | lebrikizumab | atopic dermatitis | Active | |||
TBC | zilucoplan | Generalized myasthenia gravis (gMG) | Active | |||
TBC | clindamycin plus benzoyl peroxide and adapalene | acne vulgaris | Active | |||
TBC | ivosidenib | Acute myeloid leukemia (AML) | Active | |||
TBC | sotatercept | Pulmonary arterial hypertension (WHO group 1) | Received | |||
TBC | eplontersen | Polyneuropathy in hereditary transthyretin-mediated amyloidosis | Received |